ALK submits registration application for ragweed SLIT-tablet in Europe (ALK-Abelló A/S)
(WorldNews Denmark)

(Source: ALK-Abelló A/S) Copenhagen, 2017-02-16 08:27 CET (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the European regulatory filing for its ragweed sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by the relevant health authorities via the Decentralised Procedure, with Germany as the Reference Member State. The proposed indication is for the treatment of adult patients (18-65 years) with ragweed allergic rhinitis and/or conjunctivitis, despite use of symptom-relieving medication. The data used in the filing are primarily drawn from the North...